ASH 2022 | Update on Phase II study of ibrutinib in patients with classic and variant hairy cell leukemia
Kerry Rogers, MD, The Ohio State University, Columbus, OH, outlines the updated results from a Phase II study of ibrutinib in hairy cell leukemia (HCL). Overall, the study showed that patients with both classic and variant HCL continued to benefit from treatment with ibrutinib after a median follow-up of three years. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Innate Pharma: Consultancy; Pharmacyclics: Consultancy; Beigene: Consultancy; AstraZeneca: Consultancy, Other: Travel Funding; Novartis: Research Funding; Janssen: Research Funding; AbbVie: Consultancy, Research Funding; Genentech: Consultancy, Research Funding.
